Market Cap$193.67B
P/E22.76x
PEG Ratio2.28
Div yield3.98%
Beta0.40
GILD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)1.30%
Price vs S&P 500 (4W)5.06%
PEG Ratio2.28
VGM Score65.41
P/E Ratio (Annual)22.76x
Indicated Dividend Yield (Annual)3.98%
GILD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$7.25 | -$6.75 | +6.86%(+$0.50) | |
| Q1 2026 | $1.91 | $2.03 | +6.24%(+$0.12) | |
| Q4 2025 | $1.81 | $1.86 | +2.82%(+$0.05) | |
| Q3 2025 | $2.14 | $2.47 | +15.68%(+$0.33) | |
| Q2 2025 | $1.96 | $2.01 | +2.72%(+$0.05) |
GILD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.08
4.05
4.05
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About Gilead Sciences Inc
Gilead Sciences develops therapies for life-threatening infectious diseases, with a portfolio focused on HIV and hepatitis B and C. The company's hepatitis C franchise, anchored by Sovaldi, remains a standard of care in combination regimens. Gilead is strategically expanding into oncology through recent acquisitions including CAR-T cell therapy Yescarta/Tecartus and solid tumor therapy Trodelvy.